Results 31 to 40 of about 1,677,629 (133)

Sodium Oxybate Alters Sleep Architecture and Reduces Emotional Selectivity in Memory‐Related Responses

Journal of Sleep Research, EarlyView.
ABSTRACT Sleep supports memory consolidation. Non‐rapid eye movement (NREM) and rapid eye movement (REM) sleep have been proposed to support, respectively, declarative memory consolidation and the integration of the memory affective dimension. Here, we used sodium oxybate (SXB) to modify the NREM/REM proportion during one sleep night and assessed ...
Laure Colin, Kinga Igloi, Alison Montagrin, Samika Kumar, Jeremy Hofmeister, Markus Gschwind, Sophie Schwartz, Virginie Sterpenich   +7 more
wiley   +1 more source

Postmortem Evidence of CRH Neuron Reduction in Narcolepsy Without Cataplexy With Borderline Hypocretin‐1 Levels

Journal of Sleep Research, EarlyView.
ABSTRACT Narcolepsy is classified as type 1 (NT1) or type 2 (NT2) mainly according to hypocretin deficiency rather than cataplexy. While CRH neuron loss in the PVN has been described in NT1, it remains unclear whether similar changes occur in narcolepsy without cataplexy.
Ling Shan, Suzan Linssen, Rolf Fronczek, Lucie Barateau, Christelle Peyron, Yves Dauvilliers   +5 more
wiley   +1 more source

Network Analysis in Central Disorders of Hypersomnolence: Insight Into Relationships Between Symptoms, Mental Health, and Quality of Life

Journal of Sleep Research, EarlyView.
Network Analysis in Central Disorders of Hypersomnolence: Insight Into Relationships Between Symptoms, Mental Health, and Quality of Life. ABSTRACT In the central disorders of hypersomnolence (CDH) narcolepsy types 1 and 2 (NT1, NT2) and idiopathic hypersomnia (IH), mental health problems are highly prevalent, and quality of life is decreased.
Denise Bijlenga, Tessa F. Blanken, Josephine J. de Boer, Rolf Fronczek, Gert Jan Lammers   +4 more
wiley   +1 more source

The pharmacokinetics of once-nightly controlled- release Sodium Oxybate (FT218): overview of results from four phase 1 studies

, 2019
Introduction: Sodium oxybate is an effective treatment for excessive daytime sleepiness and cataplexy in patients with narcolepsy. The approved effective doses of sodium oxybate are 6, 7.5 and 9 g per night, divided in two doses - the first taken at ...
Thorpy, M, Winkelman, J, Monteith, D, Corser, B, Dubow, J, Roth, Thomas, Grassot, J   +6 more
core   +1 more source

Implication of the thalamus in sleep alterations observed in Alzheimer's disease

Alzheimer's &Dementia, Volume 22, Issue 3, March 2026.
Abstract Alzheimer's disease (AD), the most common neurodegenerative disorder, is frequently accompanied by sleep disturbances. Alterations of sleep, in both quality and quantity, contribute to the progression of AD neuropathology. The thalamus, through its diverse nuclei, plays a central role in sleep regulation and sleep‐dependent memory ...
Carla Burnet‐Merlin, Y. Audrey Hay, Aurélie Brécier   +2 more
wiley   +1 more source

Pharmacokinetics and formulation selection of FT218, an investigational controlledrelease sodium oxybate formulation designed for once nightly dosing

, 2019
Introduction: Sodium oxybate is indicated for the treatment of Excessive Daytime Sleepiness (EDS) and cataplexy in patients with narcolepsy. The currently marketed product, an immediate release (IR) sodium oxybate is required to be taken twice nightly ...
Monteith, D, Roth, Thomas, Grassot, J, Castellan, C   +3 more
core   +1 more source

Pharmacotherapy of Narcolepsy: Focus on Sodium Oxybate

, 2010
Narcolepsy is a complex disease with multiple symptoms that include excessive daytime sleepiness, cataplexy, hypnagogic hallucinations, and sleep paralysis. Pharmacologic management of patients with narcolepsy is based on treating these symptoms. Sodium
Sanjeev V. Kothare, Joseph Kaleyias
core   +1 more source

The sodium in sodium oxybate: is there cause for concern? [PDF]

, 2020
Sodium oxybate (SO), the sodium salt of γ-hydroxybutyric acid, is one of the primary pharmacologic agents used to treat excessive sleepiness, disturbed nighttime sleep, and cataplexy in narcolepsy. The sodium content of SO ranges from 550 to 1640 mg&
Kushida, Clete A, Avidan, Alon Y
core   +1 more source

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review

Brain and Behavior, Volume 15, Issue 12, December 2025.
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Natasha Elaine Hastings, Khalil El Abdi, Fazeela Bibi, Bilal Aslam, Milka Rosario Nuñez, Muhammad Tahla Rehman Sherani, Sujeet Shadmani, Umama Alam, Vohra Maham Hassan, Hoor‐e‐Ainaa, Hania Imran, James Hanna, Said Hamid Sadat   +12 more
wiley   +1 more source

Narcolepsy 2025 (with an Australasian perspective)

Internal Medicine Journal, Volume 55, Issue 11, Page 1805-1813, November 2025.
Abstract Narcolepsy is a disorder of central hypersomnolence, which, while uncommon, can carry profound implications for affected individuals. Despite this, it remains under‐recognised within the medical community and presents frequent diagnostic and treatment challenges in the Australasian setting.
Amelia Lin, Brendon J Yee, Jian Eu Tai, Sheila Sivam   +3 more
wiley   +1 more source